Astrid Gruber, Magnus Björkholm, Lorentz Brinch, Stein Evensen, Bengt Gustavsson, Michael Hedenus, Gunnar Juliusson, Eva Löfvenberg, Ingerid Nesthus, Bengt Simonsson, Malvin Sjo, Leif Stenke, Jon Magnus Tangen, Ulf Tidefelt, Ann-Mari Udén, Christer Paul, Jan Liliemark
The cyclosporine analog Valspodar (PSC 833, Novartis Pharma) is a strong inhibitor of the mdr1 gene product p-glycoprotein (pgp). A phase I/II study was conducted in order to evaluate if addition of Valspodar to treatment with daunorubicin and cytarabine, given to patients with primary refractory or relapsed acute myeloid leukemia, could increase the complete remission rate.Fifty-three patients were treated in cohorts of three to six patients. Twelve patients reached a complete remission in bone marrow, five of whom also normalized their peripheral blood values...
April 2003: Leukemia Research